title: Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?
abstract: Cabazitaxel, a next-generation taxane, retains its efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress on new androgen receptor (AR)-targeted agents such as abiraterone acetate or enzalutamide. These findings are reinforced by in vitro preclinical data confirming cross-resistance between abiraterone and enzalutamide, but not between cabazitaxel and AR-targeted agents.
authors: European Georges Pompidou Hospital, 20 rue Leblanc, 75015 Paris, France.
authors: Stéphane
authors: S
authors: Oudard
authors: European Georges Pompidou Hospital, 20 rue Leblanc, 75015 Paris, France.
authors: Antoine
authors: A
authors: Angelergues
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000378:metabolism; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; C552428:cabazitaxel